A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale
Objective: The objective of this study is to access the efficacy of CX-8998 using the MDS-UPDRS Tremor Score (MDS-UPDRS-TS) and a digital biomarker platform, while…Trans-spinal direct current stimulation for managing primary orthostatic tremor
Objective: To evaluate in a randomized, double-blind, sham-controlled, crossover trial the efficacy of non-invasive trans-spinal direct current stimulation (tsDCS) for managing primary orthostatic tremor (POT).…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content
Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease
Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders
Objective: The objective of NS-PARK/FCRIN network (http://www.parkinson.network/) is to facilitate and stimulate clinical academic and industrial research in France in the field of Parkinson's disease…Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials
Objective: To identify and overcome challenges to recruiting minorities in Parkinson's Disease experimental therapeutic trials. Background: Inadequate representation of ethnic and minority population poses substantial…Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study
Objective: To use clinical and biological data from PPMI to estimate sample size for disease modification studies in de novo PD Background: One barrier to…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.